Nightstar Therapeutics plc (Nasdaq:NITE), a leading clinical-stage gene therapy company focused on novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness, visits the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO).
Nightstar Therapeutics plc (Nasdaq:NITE), a leading clinical-stage gene therapy company focused on novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness, visits the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO).